Bio-Techne Expands R&D Systems AI-Engineered Designer Protein …

6 days ago · MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer …

FAQs about Bio-Techne Expands R&D Systems AI-Engineered Designer Protein … Coupon?

What's new at Bio-Techne?

Bio-Techne Corporation TECH recently announced the launch of a new line of designer proteins engineered using advanced artificial intelligence (AI)- based design platforms and protein evolutionary workflows. The company’s new designer proteins are now available as part of its market-leading R&D Systems branded portfolio of proteins. ...

Why is Bio-Techne gaining synergies?

The company has been gaining synergies from its growing portfolio of designer proteins that combine cutting-edge AI technology and innovative protein engineering. Bio-Techne has five decades of proteomic leadership, protein library evolution and rational design. ...

Is Bio-Techne a good company?

Bio-Techne has five decades of proteomic leadership, protein library evolution and rational design. On a promising note, Bio-Techne is well positioned with its expanded portfolio to deliver next-generation cytokines and growth factors with tailored functionalities such as hyperactivity, enhanced receptor affinities and improved heat stability. ...

Is Bio-Techne a good stock to buy?

On a promising note, Bio-Techne is well positioned with its expanded portfolio to deliver next-generation cytokines and growth factors with tailored functionalities such as hyperactivity, enhanced receptor affinities and improved heat stability. Accordingly, we expect the latest development to boost the market sentiment toward TECH stock. ...

Will Bio-Techne stock boost market sentiment?

Accordingly, we expect the latest development to boost the market sentiment toward TECH stock. Bio-Techne has a market capitalization of $11.65 billion. The Zacks Consensus Estimate for the company’s fiscal 2025 earnings indicates a 5.1% year-over-year increase on a 5.5% revenue improvement. ...

How generative AI is transforming cellular therapy?

In the trailing four quarters, it delivered an average earnings surprise of 1.55%. Leveraging generative AI, the innovative recombinant proteins are designed and engineered to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion. ...